[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342073-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-342073-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","mrna-seq-based-analysis-predicts-aeg-1-is-a-therapeutic-target-and-immunotherapy-biomarker-for-pan-cancer-including-oscc","mRNA-seq-based analysis predicts: AEG-1 is a therapeutic target and immunotherapy biomarker for pan-cancer, including OSCC","","mRNA-seq-based analysis links AEG-1 to tumor biology and immunity across multiple cancers, with emphasis on oral squamous cell carcinoma (OSCC). Background evidence highlights AEG-1 aberrant expression in tumorigenesis, neurodegeneration, and inflammation, but its immune infiltration relationships in OSCC and other tumor types remained insufficiently characterized. Integrated database mining, single-cell RNA-seq support, and OSCC wet-lab validation connect AEG-1 levels with prognosis, immune infiltration markers, Th1/Th2 balance, glycogen accumulation, and tumor fibrosis, suggesting AEG-1 as a prognostic immune biomarker for adjuvant immunotherapy benefit.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mrna-seq-based-analysis-predicts-aeg-1-is-a-therapeutic-target-and-immunotherapy-biomarker-for-pan-cancer-including-oscc/342073/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mrna-seq-based-analysis-predicts-aeg-1-is-a-therapeutic-target-and-immunotherapy-biomarker-for-pan-cancer-including-oscc/342073.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study propose about AEG-1 in pan-cancer and OSCC?","Question",{"text":63,"@type":64},"AEG-1 is proposed to be highly expressed across multiple cancer types and to be significantly elevated in OSCC, where it correlates with patient prognosis and immune infiltration.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were AEG-1 and its immune relationships analyzed?",{"text":68,"@type":64},"The study integrates multiple cancer databases (including TIMER, GEPIA, HPA, TCGA, UALCAN, cBioPortal, SMART, and TISIDB) plus single-cell RNA-seq, then performs in vitro overexpression and OSCC mRNA-seq analyses. RT-PCR validation uses xenograft tumors, and staining methods include H&E, Masson, PAS, and immunohistochemistry.",{"name":70,"@type":61,"acceptedAnswer":71},"Which immune infiltration markers and immune processes are associated with AEG-1 in OSCC?",{"text":72,"@type":64},"In OSCC, AEG-1 correlates with immune infiltration markers such as LCP2, CD247, HLA-DPA1, HLA-DRA, HLA-DRB1, CIITA, and CD74, and it is reported to regulate Th1/Th2 immune homeostasis.",{"name":74,"@type":61,"acceptedAnswer":75},"Why is AEG-1 considered a potential biomarker for immunotherapy?",{"text":76,"@type":64},"AEG-1 shows significant association with prognosis and immune infiltration across cancer types and specifically in OSCC, supporting its value as a novel prognostic immune biomarker that may help identify patients likely to benefit from adjuvant immunotherapy.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},342073,1790125784,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Original Research PUBLISHED 17 October 2024  \nDOI 10.3389/fimmu.2024.1484226  \nOPEN ACCESS  \nEDITED BY  \nPengpeng Zhang,  \nNanjing Medical University, China  \nREVIEWED BY  \nLei Yin,  \nShanghai Jiaotong University School of Medicine, China  \nGuangyan Zhangyuan,  \nShanghai Jiao Tong University, China  \n*CORRESPONDENCE  \nXiumei Wang  \n [hrbwangmei@163.com](hrbwangmei@163.com)  \n†The authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 21 August 2024  \nACCEPTED 24 September 2024  \nPUBLISHED 17 October 2024  \nCITATION  \nYao L, Liu L, Xu W, Xi H, Lin S, Piao G, Liu Y, Guo J and Wang X (2024) mRNA-seq-based analysis predicts: AEG-1 is a therapeutic target and immunotherapy biomarker for pan-cancer, including OSCC.  \nFront. Immunol. 15:1484226 .  \ndoi: 10.3389/fimmu.2024.1484226  \nCOPYRIGHT  \n© 2024 Yao, Liu, Xu, Xi, Lin, Piao, Liu, Guo and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nmRNA-seq-based analysis predicts: AEG-1 is a therapeutic target and immunotherapy biomarker for pan-cancer, including OSCC  \nLihong Yao †, Lixue Liu †, Wanqiu Xu, Hualei Xi, Song Lin, Guiyan Piao, Ying Liu, Jinrong Guo and Xiumei Wang*  \nDepartment of Stomatology, The Second Afﬁliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China  \nBackground: The aberrant expression of AEG-1 is signiﬁcantly correlated with tumorigenesis, development, neurodegeneration and inﬂammation. However, the relationship between AEG-1 expression and immune inﬁltration in OSCC, as well as other tumor types, has yet to be comprehensively analyzed.  \nMethods: The expression levels, prognostic and clinico pathological characteristics, mutation patterns and methylation landscapes of AEG-1 in various tumors were obtained from multiple databases, including TIMER, GEPIA, HPA, TCGA, UALCAN, cBioPortal, SMART and TISIDB, in addition to single-cell RNA-seq data. The integration of these datasets facilitated the elucidation of the relationships among pan-cancer cellular heterogeneity, immune inﬁltration and AEG-1 expression levels. In vitro experiments created AEG-1 overexpressing cell lines, and mRNA-seq analyzed AEG-1-related differential genes in OSCC. RT-PCR validated these ﬁndings in vivo using xenograft tumors. Tumor cell lines were developed to study AEG-1’s effects through H&E, Masson, and PAS staining. Immunohistochemistry examined AEG- 1-related gene expression patterns.  \nResults: Our analysis demonstrated that AEG-1 is highly expressed across various cancer types and is associated with tumor grade and patient prognosis . Additionally, AEG-1 ampliﬁcation was observed in multiple cancers. Notably, we identiﬁed a signiﬁcant elevation of AEG-1 expression in OSCC, which strongly correlated with patient prognosis and immune inﬁltration. Through mRNA-seq analysis of differentially expressed genes and immune-related gene sets, weidentiﬁed a strong correlation between AEG-1 and immune inﬁltration markers such as LCP2, CD247, HLA-DPA1, HLA-DRA, HLA-DRB1, CIITA and CD74 in OSCC. Additionally, AEG-1 was found to regulate Th1/Th2 immune homeostasis, promote glycogen accumulation, and contribute to tumor ﬁbrosis.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nConclusion: In conclusion, AEG-1 signiﬁcantly correlates with prognosis and immune inﬁltration across various cancer types and holds potential as a novel prognostic immune biomarker for OSCC. This ﬁnding may facilitate the identiﬁcation of patients who are most likely to beneﬁt from adjuvant immunotherapy.  \nKEYWORDS  \nAEG-1, pan-cancer, OSCC, immune inﬁltratio","cbCaibcFnXLTLZiA","https://ap.wps.com/l/cbCaibcFnXLTLZiA","pdf",15846361,17,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Keywords\n# 1 Introduction","[{\"question\":\"What does the study propose about AEG-1 in pan-cancer and OSCC?\",\"answer\":\"AEG-1 is proposed to be highly expressed across multiple cancer types and to be significantly elevated in OSCC, where it correlates with patient prognosis and immune infiltration.\"},{\"question\":\"How were AEG-1 and its immune relationships analyzed?\",\"answer\":\"The study integrates multiple cancer databases (including TIMER, GEPIA, HPA, TCGA, UALCAN, cBioPortal, SMART, and TISIDB) plus single-cell RNA-seq, then performs in vitro overexpression and OSCC mRNA-seq analyses. RT-PCR validation uses xenograft tumors, and staining methods include H\\u0026E, Masson, PAS, and immunohistochemistry.\"},{\"question\":\"Which immune infiltration markers and immune processes are associated with AEG-1 in OSCC?\",\"answer\":\"In OSCC, AEG-1 correlates with immune infiltration markers such as LCP2, CD247, HLA-DPA1, HLA-DRA, HLA-DRB1, CIITA, and CD74, and it is reported to regulate Th1/Th2 immune homeostasis.\"},{\"question\":\"Why is AEG-1 considered a potential biomarker for immunotherapy?\",\"answer\":\"AEG-1 shows significant association with prognosis and immune infiltration across cancer types and specifically in OSCC, supporting its value as a novel prognostic immune biomarker that may help identify patients likely to benefit from adjuvant immunotherapy.\"}]","mRNA-seq-based analysis predicts: AEG-1 is a therapeutic target and immunotherapy biomarker for pan-cancer, including OSCC | PDF",1790045049,43,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dfe63e2ec33174afc75607fb7a54a01.webp",983,1389,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59f913c4a070d84f1c126265f767865d.webp",982,1388,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1afab07db37371c20eb5c5b6fb56fce.webp",981,1386,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49472ad2a7ed6222a34fe057b9a2c0fc.webp",980,1385]